Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Glaxo’s nucleoside analog 3TC

  • News

Executive Summary

Is in two Phase II/III trials in North America involving a total of 645 AIDS patients. One trial involves a comparison of three treatment groups: low dose 3TC with AZT (Burroughs Wellcome's Retrovir) versus high dose 3TC with AZT versus ddC (Roche's Hivid) with AZT in treating HIV-infected, AZT-experienced ( >/= 24 weeks) patients with CD4 cell counts of 100-300/mm. The other study involves a comparison of four arms: 3TC alone, AZT alone, low dose 3TC with AZT and high dose 3TC with AZT in HIV- infected patients, who are AZT naive ( </= 4 weeks) with CD4 cell counts of 200-500/mm. "The Pink Sheet" (Nov. 8, T&G-5) incorrectly described the total number of patients and design of the protocols.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS023591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By